CDC Issues Shared Clinical Decision-Making Guidance for RSV Vaccines Targeting Older Adults

CDC Issues Updated Recommendations for RSV Vaccination in Adults Aged 60 and Older

The CDC laid out its 2023 recommendations for RSV vaccines in older adults after the FDA approved the first of three products. The guidance calls for shared clinical decision-making between clinicians and patients aged 60 to 74 while noting stronger evidence of benefit for those 75 and older or with certain underlying conditions. Officials examined clinical trial results and early real-world data on protection against severe lower respiratory tract disease and hospitalization. The update aims to focus vaccination efforts on communities that bear the heaviest burden from RSV each season.

The MMWR report found that RSV leads to substantial morbidity and hospitalization among adults 60 and older. Those with cardiopulmonary disease, diabetes, or immunosuppression face elevated risks during winter months. [1]

The report reviewed how the vaccines perform against RSV-associated lower respiratory tract disease. Data suggest protection is clearest in the first season after vaccination. The CDC stopped short of a universal recommendation for the entire 60-and-older group. [1]

The FDA has approved three RSV vaccines for this age range. Arexvy gained approval first in May 2023. Abrysvo and mResvia followed. [2]

CDC consumer guidance states that vaccination involves a single dose. Revaccination is not recommended at this time. Longer-term effectiveness data continue to be collected. [3]

Risk factors shape decisions for adults 60 to 74. The guidance identifies chronic heart and lung conditions, diabetes, and weakened immunity as elements that increase the likelihood of severe RSV outcomes. Adults 75 and older show benefit across broader evidence regardless of other factors. [1]

Surveillance systems track rare neurologic events after vaccination. These include possible cases of Guillain-Barré syndrome. Assessments so far indicate that benefits remain higher than these risks for groups most likely to experience severe RSV disease. [1]

What this means

The guidance moves toward more individualized discussions that account for age, health status, and community impact of RSV. It reflects evidence available from one or two seasons of vaccine performance while noting that protection duration past the first year stays unknown. Early post-licensure safety data have not altered the overall benefit picture for higher-risk older adults, though trial populations did not fully represent all racial, ethnic, or frailty groups in this age range.

Key takeaways

• RSV causes substantial illness and hospitalization among adults 60 and older, especially those with cardiopulmonary disease, diabetes or immunosuppression. [1]
• All three FDA-approved vaccines demonstrate efficacy against RSV-associated lower respiratory tract disease in clinical trials. [1][2]
• Shared clinical decision-making is the framework used for adults aged 60 to 74. [1]
• Adults 75 and older or those with defined risk factors show the clearest evidence of benefit from a single dose. [1][3]
• Duration of protection beyond one season has not been established and requires future data. [3]

Limitations

Recommendations rest on one or two RSV seasons of effectiveness data. Duration of protection past that window remains uncertain. Clinical trials had limited racial and ethnic diversity and under-represented the frailest older adults. The best interval for any future dose has not been established. Rare safety signals continue to be monitored through VAERS and similar systems and will need ongoing review.

FAQ

Which specific RSV vaccines have received FDA approval for adults aged 60 and older?
Arexvy, Abrysvo and mResvia have been approved. [2]

What risk factors should guide shared clinical decision-making for adults aged 60–74?
Cardiopulmonary disease, diabetes and immunosuppression are key conditions identified in the evidence review. [1]

How do the 2023–2024 recommendations differ from prior guidance or the 2024 ACIP updates?
The update provides explicit risk stratification between adults 60–74 and those 75 and older, moving beyond the initial broader authorization. [1][3]

What safety signals are being monitored post-licensure for these vaccines?
Rare neurologic events such as Guillain-Barré syndrome remain under surveillance, though current data indicate benefits outweigh risks in high-risk groups. [1]

Sources / References

[1] Use of Respiratory Syncytial Virus Vaccines Among Older Adults, United States, 2023. https://www.cdc.gov/mmwr/volumes/72/rr/rr7203a1.htm

[2] FDA Approves First Respiratory Syncytial Virus (RSV) Vaccine. https://www.fda.gov/news-events/press-announcements/fda-approves-first-respiratory-syncytial-virus-rsv-vaccine

[3] RSV Vaccination for Older Adults. https://www.cdc.gov/vaccines/vpd/rsv/public/older-adults.html